Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bearish -20

Has The Market Rerated Moderna (MRNA) Too Quickly After Its Recent Share Price Surge? - simplywall.st

📉 DCF Analysis: A two-stage free cash flow model projects negative cash flows through 2027, implying an intrinsic value of $3.90 versus the current price of $46.71.

💰 Valuation Metrics: Moderna trades at a Price-to-Sales ratio of 8.33x, which aligns with industry peers but exceeds the platform's calculated Fair Ratio of 1.56x.

📈 Recent Performance: The stock has delivered a 91.2% return over the last year and a 51.4% return year-to-date despite weaker long-term historical returns.

🧠 Optimistic Narrative: One investor story frames recent weakness as an overreaction, highlighting a strong balance sheet and a broad mRNA pipeline with a potential fair value of $175.

⚠️ Cautious Narrative: Another perspective views current positives as reflected in the price, citing risks around vaccine demand and regulatory scrutiny with a consensus fair value near $46.10.

🏦 Financial Health: The company is noted for having low debt and a balance sheet that some analysts view as trading below book value.

Bullish Signals
  • Moderna has delivered exceptional recent performance with a 91.2% return over the last year and a 51.4% gain year-to-date.
  • The company maintains a strong balance sheet characterized by low debt levels.
  • A significant portion of the mRNA pipeline is currently in trials, suggesting future growth potential as earlier investments mature.
  • The stock trades below book value according to one optimistic valuation narrative, indicating assets may be undervalued relative to price.
  • Moderna's Price-to-Sales ratio of 8.33x is competitive and close to the Biotechs industry average of 10.82x.
Risk Factors
  • The Discounted Cash Flow model projects substantial negative free cash flows, estimating outflows of $3.2 billion in 2026 and $1.5 billion in 2027.
  • A DCF-based intrinsic value calculation suggests the stock is overvalued by approximately 1,097% compared to current market prices.
  • The proprietary Fair Ratio analysis indicates the stock is expensive relative to a calculated fair multiple of 1.56x versus the current 8.33x P/S ratio.
  • Risks include potential instability in revenue due to vaccine demand fluctuations, intense competition, and regulatory scrutiny.
  • Analyst consensus price targets sit close to the current share price, implying limited immediate upside from a neutral valuation perspective.
Full Analysis
Simply Wall St analyzes Moderna (MRNA), noting a recent surge with a 51.4% year-to-date return and a current price of $46.71. The article questions whether the market has overvalued the stock, citing a DCF model that projects significant future cash outflows until 2030, resulting in an intrinsic value of roughly $3.90 per share. This valuation suggests Moderna is significantly overvalued by approximately 1,097% based on discounted cash flow analysis. However, the stock's Price-to-Sales ratio of 8.33x is comparable to industry and peer averages, though it exceeds the platform's proprietary 'Fair Ratio' of 1.56x, indicating potential expense relative to growth expectations. The article presents two contrasting investment narratives for Moderna. An optimistic view sees a strong balance sheet and a transition period following COVID-19 revenue pullbacks, implying a fair value near $175. Conversely, a cautious narrative views current positives as fully priced in, flags risks like competition and pricing pressure, and suggests the stock is fairly valued at roughly $46.10.